A Multicenter, Randomized, Single-masked Study Comparing Reduced-fluence Visudyne-Lucentis Combination Therapies and Lucentis Monotherapy in Subjects With Choroidal Neovascularization (CNV) Secondary to AMD.

Trial Profile

A Multicenter, Randomized, Single-masked Study Comparing Reduced-fluence Visudyne-Lucentis Combination Therapies and Lucentis Monotherapy in Subjects With Choroidal Neovascularization (CNV) Secondary to AMD.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2014

At a glance

  • Drugs Verteporfin (Primary) ; Dexamethasone; Ranibizumab
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms RADICAL
  • Sponsors QLT
  • Most Recent Events

    • 26 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top